Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 261-693-5 | CAS number: 59312-61-7
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: Assessment based on physicochemical properties and toxicological data
- Adequacy of study:
- supporting study
- Study period:
- 2017
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Objective of study:
- absorption
- distribution
- excretion
- metabolism
- toxicokinetics
- Principles of method if other than guideline:
- Assessment based on physicochemical properties and toxicological data
- GLP compliance:
- no
- Conclusions:
- Disperse Yellow 114 would be absorbed primarily in gastrointestinal tract, while limited absorption via dermal and inhalation exposure can be expected at high doses. Systemic distribution would most likely occur along the gastrointestinal tract. Predominant route of excretion is expected to be through faeces, however, it may get metabolized to a more hydrophilic product and may also get excreted via urine at high doses.
- Executive summary:
Disperse Yellow 114 would be absorbed primarily in gastrointestinal tract, while limited absorption via dermal and inhalation exposure can be expected at high doses. Systemic distribution would most likely occur along the gastrointestinal tract. Predominant route of excretion is expected to be through faeces, however, it may get metabolized to a more hydrophilic product and may also get excreted via urine at high doses.
Reference
Description of key information
Disperse Yellow 114 would be absorbed primarily in gastrointestinal tract, while limited absorption via dermal and inhalation exposure can be expected at high doses. Systemic distribution would most likely occur along the gastrointestinal tract. Predominant route of excretion is expected to be through faeces, however, it may get metabolized to a more hydrophilic product and may also get excreted via urine at high doses.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
